WO2002101076A3 - Methods for targeted expression of therapeutic nucleic acid - Google Patents

Methods for targeted expression of therapeutic nucleic acid Download PDF

Info

Publication number
WO2002101076A3
WO2002101076A3 PCT/US2002/018650 US0218650W WO02101076A3 WO 2002101076 A3 WO2002101076 A3 WO 2002101076A3 US 0218650 W US0218650 W US 0218650W WO 02101076 A3 WO02101076 A3 WO 02101076A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
methods
therapeutic nucleic
expression vectors
targeted expression
Prior art date
Application number
PCT/US2002/018650
Other languages
French (fr)
Other versions
WO2002101076A2 (en
Inventor
Richard R Drake
Saurabh K Gupta
Kelly E Mercer
Robyn Mcmasters
Mary Pat Moyer
Original Assignee
Eastern Virginia Med School
Univ Arkansas
Incell Corp Llc
Richard R Drake
Saurabh K Gupta
Kelly E Mercer
Robyn Mcmasters
Mary Pat Moyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Med School, Univ Arkansas, Incell Corp Llc, Richard R Drake, Saurabh K Gupta, Kelly E Mercer, Robyn Mcmasters, Mary Pat Moyer filed Critical Eastern Virginia Med School
Priority to JP2003503826A priority Critical patent/JP2005504520A/en
Priority to AU2002345658A priority patent/AU2002345658A1/en
Priority to CA002460095A priority patent/CA2460095A1/en
Priority to EP02744307A priority patent/EP1461427A4/en
Publication of WO2002101076A2 publication Critical patent/WO2002101076A2/en
Publication of WO2002101076A3 publication Critical patent/WO2002101076A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Expression vectors that include a pre-selected therapeutic nucleic acid operably linked to a tumor specific or cell type-speci fic promoter and a Tcf-4β-catenin enhancer are provided. The therapeutic nucleic acid preferably includes a gene encoding a therapeutic protein for treatment of, for example, cancer. Methods for targeted expression of therapeutic nucleic acid, and methods for treating cancer, utilizing the expression vectors described herein, are also provided. Host cells are also provided that have been transformed with the expression vectors described herein.
PCT/US2002/018650 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid WO2002101076A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003503826A JP2005504520A (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acids
AU2002345658A AU2002345658A1 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid
CA002460095A CA2460095A1 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid
EP02744307A EP1461427A4 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29783101P 2001-06-13 2001-06-13
US60/297,831 2001-06-13
US36113702P 2002-03-01 2002-03-01
US60/361,137 2002-03-01

Publications (2)

Publication Number Publication Date
WO2002101076A2 WO2002101076A2 (en) 2002-12-19
WO2002101076A3 true WO2002101076A3 (en) 2004-07-22

Family

ID=26970335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/018650 WO2002101076A2 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid

Country Status (5)

Country Link
EP (1) EP1461427A4 (en)
JP (1) JP2005504520A (en)
AU (1) AU2002345658A1 (en)
CA (1) CA2460095A1 (en)
WO (1) WO2002101076A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041350A2 (en) * 2005-10-01 2007-04-12 Charles Stout Regulatable fusion promoters
MX2015013590A (en) * 2013-03-24 2016-06-06 Oisin Biotechnologies Systems and methods for the targeted production of a therapeutic protein within a target cell.
WO2017205395A1 (en) * 2016-05-25 2017-11-30 The Board Of Trustees Of The Leland Stanford Junior University Activity-dependent expression constructs and methods of using the same
CA3047140A1 (en) 2017-01-09 2018-07-12 Oisin Biotechnologies Constructs for expression of therapeutic proteins in target cells
WO2019204666A1 (en) 2018-04-18 2019-10-24 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell
CN110964747A (en) * 2019-11-26 2020-04-07 深圳市人民医院 Suicide gene adenovirus with high-efficiency specific expression in glioma cell and construction method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
US6140052A (en) * 1997-03-20 2000-10-31 The Johns Hopkins University cMYC is regulated by Tcf-4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
CA2401533A1 (en) * 2000-03-02 2001-09-07 M.L. Laboratories Plc Tcf responsive element

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
US6140052A (en) * 1997-03-20 2000-10-31 The Johns Hopkins University cMYC is regulated by Tcf-4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1461427A4 *

Also Published As

Publication number Publication date
JP2005504520A (en) 2005-02-17
EP1461427A2 (en) 2004-09-29
WO2002101076A2 (en) 2002-12-19
EP1461427A4 (en) 2006-02-15
AU2002345658A1 (en) 2002-12-23
CA2460095A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
WO2001072957A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2003000928A3 (en) Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
WO2006050211A3 (en) Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2002059373A3 (en) Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2005047458A3 (en) Modified recombinant vaccina viruses and other microorganisms, uses thereof
WO2002010382A3 (en) Trp8, trp9 and trp10, markers for cancer
AU1254795A (en) Tumor necrosis factor-gamma
WO2004050707A3 (en) Tumor-specific recognition molecules
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
WO2005000087A3 (en) Gene products differentially expressed in cancerous colon cells and their methods of use ii
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO1997022695A3 (en) Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer
WO2000053776A3 (en) Human kallikrein-like genes
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid
WO2003085087A8 (en) Modified cea nucleic acid and expression vectors
WO1999046374A3 (en) Human nucleic acid sequences from prostate tumour tissue
WO2004092212A3 (en) Tumor antigens bfa5 for prevention and/or treatment of cancer
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2005042719A3 (en) Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents
WO2004013313A3 (en) Antisense nucleic acids
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
WO1995027070A1 (en) Dna expression vectors for use in the treatment of vascular diseases by gene therapy
WO2000029589A8 (en) Methioninase gene therapy for tumor treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2460095

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003503826

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002744307

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002744307

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002744307

Country of ref document: EP